Lonsurf’s efficacy was analyzed in a double-blind study, according to the report. Patients receiving the newly-approved drug lived an average of 7.1 months, while patients treated with a placebo lived an average of 5.3 months.
More articles on gastroenterology:
5 recent GI study findings to know
New drug shows potential in fighting C. diff: 4 notes
10 of the biggest GI/endoscopy stories in 2015
